Ciprofloxacin/hydrocortisone
| Combination of | |
|---|---|
| Ciprofloxacin | Antibacterial |
| Hydrocortisone | Anti-inflammatory |
| Clinical data | |
| Trade names | Cipro Hc |
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a607009 |
| License data | |
| Routes of administration | Auricular (otic) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Ciprofloxacin/hydrocortisone, sold under the brand name Cipro Hc among others is a fixed-dose combination medication used for the treatment of otitis externa.[1][2] It contains ciprofloxacin, as the salt ciprofloxacin hydrochloride, an antibacterial; and hydrocortisone, an anti-inflammatory corticosteroid.[1]
Ciprofloxacin/hydrocortisone was approved for medical use in the United States in February 1998.[3]
Medical uses
Ciprofloxacin/hydrocortisone is indicated for the treatment of acute otitis externa due to susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis.[1]
References
- ^ a b c d "Cipro Hc- ciprofloxacin hydrochloride and hydrocortisone suspension/ drops". DailyMed. 8 November 2024. Retrieved 11 November 2025.
- ^ Beers SL, Abramo TJ (April 2004). "Otitis externa review". Pediatric Emergency Care. 20 (4): 250–256. doi:10.1097/01.pec.0000121246.99242.f5. PMID 15057182.
- ^ "Drug Approval Package: Cipro HC Otic/Ciprofloxacin Hydrochloride & Hydrocortisone NDA# 20-805". U.S. Food and Drug Administration (FDA). 30 March 2001. Retrieved 11 November 2025.